Elekta AB stock: Trading at a potential 48% discount to fair value

Is Elekta AB's current price overlooking its strong position in radiation therapy? You get the full picture on this Swedish medtech leader's business, risks, and what global investors should watch. ISIN: SE0000163628

Elekta AB stock looks compelling right now if you're hunting for undervalued plays in medtech. Trading around SEK54 on the Nasdaq Stockholm in SEK, the shares may sit at a 48% discount to their estimated fair value of SEK105, according to fundamental analysis. This gap could signal opportunity in a company dominating precision radiation therapy for cancer treatment, but you need to weigh the trends and risks carefully.

As of: 08.04.2026

By Elena Harper, Senior Medtech Analyst: Elekta AB leads in radiation oncology solutions, powering treatments that save lives worldwide from its Swedish base.

What Elekta AB Does and Why It Matters

Elekta AB develops and sells advanced medical technology focused on radiation therapy. You know cancer treatment is evolving fast, and Elekta sits at the heart of it with systems like linear accelerators that deliver precise radiation doses to tumors while sparing healthy tissue. Their portfolio includes everything from hardware to software for planning and monitoring treatments, serving hospitals and clinics globally.

The company operates out of Stockholm, Sweden, with the shares listed as EKTA B on Nasdaq Stockholm in Swedish kronor (SEK). As the issuer, Elekta AB (publ) is the core listed entity—no complex holding structures here. This setup gives you straightforward exposure to a leader in oncology tech, where demand rises with aging populations and rising cancer rates worldwide.

Why does this matter to you as an investor? Radiation therapy is a cornerstone of cancer care, used in about half of all cases. Elekta's innovations, like adaptive radiotherapy that adjusts in real-time, position it to capture growth in a market projected to expand steadily. If you're building a portfolio with defensive healthcare exposure, this is a name to track closely.

Business Model and Key Markets

Elekta's revenue comes mainly from selling and servicing radiation therapy equipment. Think high-value systems installed in cancer centers, generating recurring income from maintenance contracts and software upgrades. This model provides stability—you get upfront sales plus years of annuity-like service fees, smoothing out cycles in healthcare spending.

Geographically, North America and Europe drive the bulk, but emerging markets like Asia add growth potential. Elekta targets big players: leading hospitals, academic centers, and even veterinary applications through partnerships. Recent mentions highlight their role in veterinary stereotactic radiosurgery alongside firms like Accuray, showing diversification beyond human medicine.

For you in the US or Europe, Elekta's global footprint means currency swings and regulatory approvals shape performance. FDA nods for US sales and CE marks for Europe keep the pipeline flowing. The company's push into AI-driven treatment planning enhances efficiency, appealing to cost-conscious providers everywhere.

Competitive Edge in Precision Oncology

Elekta competes with Varian (now part of Siemens Healthineers) and Accuray in a niche but high-stakes arena. What sets Elekta apart? Their Harmony and Versa HD platforms offer unmatched precision, integrating imaging and delivery for sub-millimeter accuracy. This edge helps oncologists treat complex cases like brain or prostate cancers more effectively.

Partnerships amplify this strength. For instance, integration with MIM Software enhances workflow across platforms, making Elekta's systems more versatile. You benefit from a moat built on clinical data—thousands of installations worldwide validate their tech, creating network effects as more centers standardize on Elekta.

In a consolidating industry, Elekta's scale matters. They invest heavily in R&D, about 10-12% of sales historically, fueling upgrades like Unity, their MRI-guided system. For global investors, this positions Elekta to ride the shift toward personalized, data-driven cancer care.

Current Valuation and Investment Case

At recent levels around SEK54, Elekta trades at a notable discount to fair value estimates. Analysts using discounted cash flow models peg intrinsic worth near SEK105, implying upside if execution holds. This valuation reflects short-term pressures but overlooks long-term tailwinds in oncology demand.

Recent trading shows volatility—a 1.98% gain to SEK48.40 in July 2025, with support at key levels. Short-term trends point lower, but buy signals from pivots suggest potential rebounds. For you, the question is timing: does the discount justify entry now, or wait for catalysts?

Relevance today? Healthcare stocks like Elekta offer resilience amid economic uncertainty. With cancer incidence climbing 1-2% annually globally, revenue visibility is strong. If you're allocating to medtech, this discount could make Elekta a buy for patient portfolios aiming 5-10% annual growth.

Analyst Views on Elekta AB

Analysts see value in Elekta's positioning, with fair value estimates highlighting a 48% upside from SEK54 levels. Technical outlooks mix caution—short-term sell signals from MACD and moving averages—with longer-term optimism on fundamentals. Reputable sources note the stock's controlled movements and low risk profile due to good liquidity.

No recent upgrades or specific price targets from major banks like SEB or Nordea appear in current public data, but the consensus leans toward hold with upside potential if trends reverse. You should monitor for fresh coverage, as medtech peers trade at premiums Elekta could close. Overall, the undervaluation thesis resonates across analyses.

Risks and What to Watch Next

No stock is without hurdles, and Elekta faces supply chain pressures and reimbursement shifts. Delays in hospital capex cycles, especially in Europe, can slow sales. Competition intensifies too—Varian's scale post-acquisition challenges market share.

Regulatory risks loom: any FDA hiccups delay US launches, a key market. Currency exposure, with SEK weakness, impacts reported earnings for global ops. Watch quarterly results for service revenue growth and order backlog—these signal demand health.

For you investing from the US, Europe, or elsewhere, track oncology spending trends and Elekta's pipeline milestones. Upcoming earnings or partnership news could spark moves. Diversify, but if the discount persists, Elekta merits a spot on your radar.

Should You Buy Elekta AB Stock Now?

Ultimately, yes if you believe in medtech's growth and see the valuation gap closing. The business is solid, with tailwinds from cancer demographics and tech leadership. But time your entry around technical support and news flow—patience pays here.

Monitor Nasdaq Stockholm for EKTA B in SEK, and cross-check with global indices for sentiment. As a global investor, Elekta fits value strategies blending growth and defense. Stay informed, assess your risk tolerance, and consider it for 10-20% portfolio weight in healthcare.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.